Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ADX10059: Phase IIa data

In a double-blind, U.K. Phase IIa trial in 50 patients, ADX10059 missed the primary endpoint

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE